FDA approves first vaccine for pregnant women to prevent RSV in infants

The Food and Drug Administration announced approval of Pfizer’s Abrysvo respiratory syncytial virus vaccine. Abrysvo is the first vaccine approved for use in pregnant individuals to prevent lower respiratory tract disease caused by RSV in infants from birth through six months of age. Individuals can receive a single dose injection when they are between 32 and 36 weeks pregnant. (FDA news release, 8/21/23)